Aeglea BioTherapeutics
is rapidly developing combination products given clinical evidence of substantial efficacy enhancement | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
July 2023
Slide
11 of 56
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
September 2023
is rapidly developing combination products given clinical evidence of substantial efficacy enhancement | Aeglea BioTherapeutics
Mergers and Acquisitions
June 2023
is rapidly developing combination products given clinical evidence of substantial efficacy enhancement | Aeglea BioTherapeutics
Related slides by other companies
Taysha
IPO
September 2020
efficacy outperformed unregulated in mouse survival study | Taysha
Dare Bioscience
Investor Presentation
February 2023
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
Matinas BioPharma
Investor Presentation
January 2024
enact phase clinical validation of safety and efficacy | Matinas BioPharma
argenx SE
Results
June 2023
for multifocal motor neuropathy advancing phase study to cohort a | argenx SE
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Mergers and Acquisitions
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights